In conclusion, we identified that the subset of patients with EGFR-mutant advanced NSCLC with concomitant mutations in tumor suppressor genes could derive more survival benefit from the addition of bevacizumab to their EGFR-TKI regimen. Here, EGFR is linked to non-small cell lung carcinoma.